AbbVie (ABBV) EPS (Weighted Average and Diluted) (2012 - 2026)
AbbVie (ABBV) reported EPS (Weighted Average and Diluted) of $0.39 for Q1 2026, down 45.83% year-over-year from $0.72 in Q1 2025, and down 61.76% on a QoQ basis from $1.02 in Q4 2025.
AbbVie (ABBV) has 15 years of EPS (Weighted Average and Diluted) data on file, last reported at $0.39 in Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) fell 45.83% year-over-year to $0.39 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.03 (down 13.62% YoY) and the FY2025 annual result came in at $2.36, down 1.26% from the prior year.
- EPS (Weighted Average and Diluted) declined to $0.39 in Q1 2026 per ABBV's latest filing, from $1.02 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at $2.51 in Q1 2022 and bottomed at -$0.02 in Q4 2024.
- The 5-year median for EPS (Weighted Average and Diluted) is $0.77 (2024), against an average of $0.85.
- The widest annual swing landed in 2024, when EPS (Weighted Average and Diluted) sank 104.35%; it then surged 5200.0% in 2025.
- Tracing ABBV's EPS (Weighted Average and Diluted) over 5 years: stood at $1.38 in 2022, then tumbled by 66.67% to $0.46 in 2023, then plunged by 104.35% to -$0.02 in 2024, then surged by 5200.0% to $1.02 in 2025, then plunged by 61.76% to $0.39 in 2026.
- Per Business Quant, the three latest ABBV EPS (Weighted Average and Diluted) figures stand at $0.39 (Q1 2026), $1.02 (Q4 2025), and $0.1 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 8.26 |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 0.39 |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -1.72 |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 3.34 |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 1.61 |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 0.47 |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 1.31 |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.39 |
| Dec 31, 2025 | 1.02 |
| Sep 30, 2025 | 0.10 |
| Jun 30, 2025 | 0.52 |
| Mar 31, 2025 | 0.72 |
| Dec 31, 2024 | -0.02 |
| Sep 30, 2024 | 0.88 |
| Jun 30, 2024 | 0.77 |
| Mar 31, 2024 | 0.77 |
| Dec 31, 2023 | 0.46 |
| Sep 30, 2023 | 1.00 |
| Jun 30, 2023 | 1.14 |
| Mar 31, 2023 | 0.13 |
| Dec 31, 2022 | 1.38 |
| Sep 30, 2022 | 2.21 |
| Jun 30, 2022 | 0.51 |
| Mar 31, 2022 | 2.51 |
| Dec 31, 2021 | 2.26 |
| Sep 30, 2021 | 1.78 |
| Jun 30, 2021 | 0.42 |
| Mar 31, 2021 | 1.99 |
| Dec 31, 2020 | 0.01 |
| Sep 30, 2020 | 1.29 |
| Jun 30, 2020 | -0.46 |
| Mar 31, 2020 | 2.02 |
| Dec 31, 2019 | 1.88 |
| Sep 30, 2019 | 1.26 |
| Jun 30, 2019 | 0.49 |
| Mar 31, 2019 | 1.65 |
| Dec 31, 2018 | -1.23 |
| Sep 30, 2018 | 1.81 |
| Jun 30, 2018 | 1.26 |
| Mar 31, 2018 | 1.74 |
| Dec 31, 2017 | 0.03 |
| Sep 30, 2017 | 1.01 |
| Jun 30, 2017 | 1.19 |
| Mar 31, 2017 | 1.06 |
| Dec 31, 2016 | 0.85 |
| Sep 30, 2016 | 0.97 |
| Jun 30, 2016 | 0.98 |
| Mar 31, 2016 | 0.83 |
| Dec 31, 2015 | 0.92 |
| Sep 30, 2015 | 0.74 |
| Jun 30, 2015 | 0.83 |
| Mar 31, 2015 | 0.63 |
| Dec 31, 2014 | -0.51 |
| Sep 30, 2014 | 0.31 |
| Jun 30, 2014 | 0.68 |
| Mar 31, 2014 | 0.61 |
| Dec 31, 2013 | 0.70 |
| Sep 30, 2013 | 0.60 |
| Jun 30, 2013 | 0.66 |
| Mar 31, 2013 | 0.60 |
| Dec 31, 2012 | 0.98 |
| Sep 30, 2012 | 1.01 |
| Jun 30, 2012 | 0.80 |
| Mar 31, 2012 | 0.56 |